Kumar Praveen, Ruhl Jennifer, Chiddarwar Tanvi V, Garibay-Treviño David U, Chowdhury Krishna Roy, Osei Prince P, Alarid-Escudero Fernando, Jacobs Bruce L, Kuntz Karen M, Jalal Hawre
University of Pittsburgh, Pittsburgh, PA, United States.
National Cancer Institute, Bethesda, MD, United States.
Cancer Epidemiol Biomarkers Prev. 2025 Jul 11. doi: 10.1158/1055-9965.EPI-25-0210.
Coding changes in disease definitions have influenced trends in bladder cancer epidemiologic outcomes in registries. The Surveillance, Epidemiology, and End Results (SEER) Program introduced a harmonized staging variable (available by request to the SEER Program) for long-term trend analysis. This study analyzes trends in bladder cancer incidence using the harmonized staging variable.
Using SEER 12 registry data, we compared trends in the incidence of bladder cancer cases diagnosed during 1992-2019 using the revised (or harmonized) staging variable against the original staging variables (SEER modified AJCC 3rd edition for 1992-2003, Derived AJCC 6th edition for 2004-15, Derived SEER Combined for 2016-17, Derived EOD 2018 for 2018-2019). We used JoinPoint regression to analyze changes in trends.
The data availability has improved with the revised staging system as the proportion of cases with missing N (lymph node), and M (metastasis) stages was substantially reduced. However, the trends varied by T stages between the two systems. There were generally more discontinuities in trends with the original system than with the revised system. Unlike the trend observed with the original staging system, the harmonized staging system has shown a 4% annual decrease in Tis incidence since 1992.
With the revised variable, we observed a consistent decrease in the incidence of Tis cases, and the trends appear smoother.
Our study highlights the benefits of using revised staging variables to reveal previously hidden patterns, supporting the use of new variables for a more nuanced understanding of temporal trends in epidemiology.
疾病定义中的编码变化影响了登记处膀胱癌流行病学结果的趋势。监测、流行病学和最终结果(SEER)计划引入了一个统一的分期变量(可应要求向SEER计划获取)用于长期趋势分析。本研究使用该统一分期变量分析膀胱癌发病率趋势。
利用SEER 12登记处数据,我们将1992 - 2019年期间诊断的膀胱癌病例发病率趋势,使用修订(或统一)分期变量与原始分期变量(1992 - 2003年为SEER修订的美国癌症联合委员会第3版,2004 - 15年为衍生的美国癌症联合委员会第6版,2016 - 17年为衍生的SEER合并版,2018 - 2019年为衍生的EOD 2018)进行比较。我们使用JoinPoint回归分析趋势变化。
随着修订后的分期系统,数据可用性得到改善,因为N(淋巴结)和M(转移)分期缺失病例的比例大幅降低。然而,两个系统之间的趋势因T分期而异。与修订系统相比,原始系统的趋势通常有更多间断点。与原始分期系统观察到的趋势不同,自1992年以来,统一分期系统显示Tis发病率每年下降4%。
使用修订后的变量,我们观察到Tis病例发病率持续下降,且趋势似乎更平滑。
我们的研究强调了使用修订后的分期变量揭示先前隐藏模式的益处,支持使用新变量更细致地理解流行病学的时间趋势。